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Methods 
•  A web-survey (Qualtrics ®) of non-institutionalised individuals with MS.   
•  14 patient associations (at national or supra-national level) were invited to cascade the surveys 
to their network of patients.  
•  Survey collected data on i) Demographics, ii)type of MS (i.e. Relapsing Remitting MS – 
RRMS, Primary Progressive MS – PPMS, Secondary Progressive MS – SPMS), iii)QoL 
(EuroQoL 5-domain; EQ-5D-5L) and EQ-5D-5L VAS, iv) Other, non EQ-5D domains which  
impacted greatly on their wellbeing and respondents thought were not captured by the EQ-5D 
and v) aspects that changed over the course of patients’ illness  
•  Microsoft® Excel 2010 was used to generate descriptive statistics  
Background & Objectives 
Multiple Sclerosis (MS) is the second most common cause of neurological disability and highest per capita costs 
among all other neurological disorders [1]. By imposing pre-defined domains on Health Related Quality of Life 
(HRQoL)  measurement EQ-5D-5L  is believed to lack dimensions of HRQL that may be impacted by chronic 
diseases such as MS, including dexterity, social functioning and vitality and therefore, raises questions as to the 
extent to which it represents the pragmatic Quality of Life (QoL) of patients [2-4] which is shaped by a unique 
combination of different important aspects for each individual.  
 
v  This study aimed to assess the extent to which MS patients consider that EQ-5D, a generic HRQoL 
measurement tool, captures the dimensions that are important to their wellbeing.  
Results 
•  246 responses from France (n=97), USA (n=70), Romania (n=44), UK (n=25) and Germany (n=10).  
•  Average EQ-5D-5L index and VAS scores were 0.60 (±0.12) and 63 (±4.7) respectively and Health State Utility Values (HSUVs) ranged from 
0.77 in Germany to 0.49 in France, and from 0.63 for RRMS, 0.51 for SPMS and 0.21 for PPMS patients.  
 
v  Important wellbeing aspects not captured by EQ-5D-5L 
•  Evaluation of the EQ-5D-5L tool showed that 97% (n=237) of all patients who responded to the question; “which aspects of their illness had a big 
impact on their health, that were not captured by the EQ-5D-5L”, consider this instrument insufficient in capturing all of the important wellbeing aspects 
that added a significant burden to their HRQoL and this percentage fluctuated between types of MS amounting up to nearly 100% for SPMS, 95% for 
PPMS and just above 96% for RRMS patients (Figure 1). 
•  Such aspects mainly included fatigue (79% of respondents), balance & dizziness (62%), tingling & numbness (61%) and bladder 
problems (55%) (Figure 3). Less commonly reported aspects included vision (41%), bowel problems (31% ), sexual discomfort (30%) and 
Maintenance of relationships (24%).  
•  Fatigue was the most commonly reported aspect not captured by EQ-5D-5L across all disease types. Other items not captured by EQ-5-5L 
fluctuated between the different types of MS (Figure 4).  
 
v  Important wellbeing aspects that changed over the course of patients’ illness 
•  57% (n=145) of all patients who responded consider that the aspects of their illness that have a big impact on their health have changed over 
the course of their disease and this percentage fluctuated between types of MS (Figure 2).  
•  Mobility and Usual activities were the most common EQ-5D-5L items that changed over the course of patients’ illness (51% and 43% 
respectively), whereas Fatigue and Balance/Dizziness were the most common non- EQ-5D-5L items (48% and 45% respectively) (Figure 5).  
•  Other less commonly reported aspects that changed included Vision (27%) and Bowel (f22%) problems, along with sexual dysfunction (23%) 
and maintenance of relationships/social life (19%) (Figure 5).  
Conclusions & Future directions 
Our analysis highlights that utilisation of the EQ-5D-5L in HRQoL  
measurement might fail to capture key QoL attributes in MS patient  
populations. However, as our study has limitations (i.e. the use of a web- 
survey resulted in data unable to be verified by the author and raised  
issues related to the patients’ understanding of the EQ-5D domains and  
their severity levels) our results should be interpreted with caution.  
 
v Further mapping of MS patients’ utilities against EQ-5D-5L and other  
generic HRQoL tools is required in order to ensuret that these  
instruments capture all QoL aspects important to MS patients.  
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Figure 1. Proportion of patients across all sample and types of MS reporting aspects not 
captured by the EQ-5D-5L 
Figure 2. Proportion of patients across all sample and types of MS reporting that important QoL 
aspects changed over the course of their illness  
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Figure 3. Most commonly reposted QoL aspects across all sample, 
which according to the respondents were not captured by the 
EQ-5D-5L 
Figure 4. Most commonly reposted QoL aspects across types of MS, which  were not captured by the EQ-5D-5L 
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Figure 5.. Most common EQ-5D-5L and non-EQ-5D-5L aspects of patients' illness that had a 
big impact on their health and that changed over the course of their disease 
Acknowledgments   
We are grateful to the MS Society UK, MS Trust UK, National MS Society (NMSS), the 
European MS Platform (EMSP), the Romanian Association of MS, the Rocky Mountain 
MS Foundation ARSEP – French MS Research Society– who facilitated data collection 
and also, to all the anonymous respondents who provided the information and insights 
captured in the study. Finally, we thank F. Hoffmann-La Roche that provided the 
sponsorship to carry out this research.  
